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Background-—Aldosterone may have adverse effects in the myocardium and vasculature. Treatment with an aldosterone
antagonist reduces cardiovascular risk in patients with acute myocardial infarction complicated by heart failure (HF) and left
ventricular systolic dysfunction. However, most patients with acute coronary syndrome do not have advanced HF. Among such
patients, it is unknown whether aldosterone predicts cardiovascular risk.
Methods and Results-—To address this question, we examined data from the dal-OUTCOMES trial that compared the cholesteryl
ester transfer protein inhibitor dalcetrapib with placebo, beginning 4 to 12 weeks after an index acute coronary syndrome. Patients
with New York Heart Association class II (with LVEF <40%), III, or IV HF were excluded. Aldosterone was measured at randomization
in 4073 patients. The primary outcome was a composite of coronary heart disease death, nonfatal myocardial infarction, stroke,
hospitalization for unstable angina, or resuscitated cardiac arrest. Hospitalization for HF was a secondary endpoint. Over a median
follow-up of 37 months, the primary outcome occurred in 366 patients (9.0%), and hospitalization for HF occurred in 72 patients
(1.8%). There was no association between aldosterone and either the time to first occurrence of a primary outcome (hazard ratio
for doubling of aldosterone 0.92, 95% confidence interval 0.78-1.09, P=0.34) or hospitalization for HF (hazard ratio 1.38, 95% CI
0.96-1.99, P=0.08) in Cox regression models adjusted for covariates.
Conclusions-—In patients with recent acute coronary syndrome but without advanced HF, aldosterone does not predict major
cardiovascular events.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00658515. ( J Am Heart Assoc. 2017;6:
e004119. DOI: 10.1161/JAHA.116.004119.)
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A ldosterone is a mineralocorticoid hormone ordinarilysecreted by the adrenal gland to maintain physiologic
levels of sodium, potassium, and blood volume. In heart
failure, secretion of aldosterone may become maladaptive,
promoting excessive sodium retention and blood volume. In
addition, sustained high levels of aldosterone may exert direct
adverse effects on the arterial wall by promoting vascular
remodeling with fibrosis and calcification1-3 and in myocar-
dium by decreasing contractility and promoting coronary
vasoconstriction4,5 and fibrosis that may provide the
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substrate for arrhythmias.6-8 Acting in the central nervous
system, aldosterone may stimulate neural pathways that
promote hypertension and sodium retention.9-11
Plasma aldosterone concentrations are elevated in
patients with acute myocardial infarction.12,13 Prior small
studies have associated elevated aldosterone at the time of
acute myocardial infarction with increased short- and long-
term risk of adverse cardiovascular outcomes.13-16 However,
these studies have had 2 principal limitations. First,
aldosterone levels are in flux during the early period after
myocardial infarction,12 affected by changing hemodynamic,
neurohumoral, and pharmacologic conditions. Therefore,
measurements of aldosterone immediately following myocar-
dial infarction may not reflect the steady-state levels
attained when patients are clinically stable and evidence-
based treatments have been implemented. Second, prior
studies included patients with congestive heart failure and
low ejection fraction, for whom a risk associated with
elevated aldosterone and a benefit of aldosterone antago-
nism have been clearly established.17 However, a majority of
patients with an acute coronary syndrome (ACS) do not
develop heart failure. It is unknown whether aldosterone
levels predict subsequent cardiovascular risk in such
patients. The recent Aldosterone Lethal Effects Blockade in
Acute Myocardial Infarction Treated With or Without Reper-
fusion to Improve Outcome and Survival at Six Months’
Follow-Up (ALBATROSS) trial failed to demonstrate a benefit
of early treatment with aldosterone antagonists after ACS
in patients without overt heart failure, but did not assess
the relationship of aldosterone levels to outcomes or the
interaction of treatment assignment and aldosterone on
outcomes.18
In this report we sought to bridge a gap in evidence by
examining the relationship between plasma aldosterone and
the risk of cardiovascular events in a large cohort of patients
who were clinically stable after recent ACS and without
advanced stages of heart failure.
Methods
Study Population
The dal-OUTCOMES trial was a randomized, double-blind trial
comparison of dalcetrapib, a cholesteryl ester transfer protein
(CETP) inhibitor, with placebo in 15 871 patients with recent
ACS (acute myocardial infarction or unstable angina pectoris).
Trial design and principal results have been described
previously.19,20 The study was performed between 2008 and
2012 at 935 sites in 27 countries; the institutional review
board of each site approved the study, and all subjects
provided informed consent. Qualifying patients were at least
45 years of age, were clinically stable at the time of
randomization, and had completed all planned coronary
revascularization procedures. Importantly, the trial excluded
patients with New York Heart Association Class III or IV
symptoms of heart failure and those with Class II symptoms
and left ventricular ejection fraction ≤40%; ie, patients who
would ordinarily have an indication for treatment with an
aldosterone antagonist were excluded. Other exclusions
included uncontrolled hypertension (systolic blood pressure
≥180 mm Hg and/or diastolic blood pressure ≥110 mm Hg
despite treatment) or serum creatinine >2.2 mg/dL
(194.5 lmol/L). Randomization and acquisition of baseline
laboratory data occurred 4 to 12 weeks (median 6 weeks)
after the index ACS and when patients were deemed clinically
stable.
The current post hoc analysis comprises 4073 patients
who were among the first to be enrolled in dal-OUTCOMES
and had a measurement of plasma aldosterone at random-
ization. The analysis cohort excluded 59 patients who were
treated with an aldosterone antagonist either at randomiza-
tion or during the follow-up period. Aldosterone was measured
in dal-OUTCOMES because another CETP inhibitor, torce-
trapib, had been shown to raise aldosterone levels and to
promote hypertension.21,22 After the independent Data Safety
and Monitoring Board determined that dalcetrapib had no
effect on aldosterone concentrations, measurements were
not performed on subsequent patients enrolled in the dal-
OUTCOMES trial.
Aldosterone Measurements
Aldosterone was measured in the supine position at random-
ization. Analysis was performed by radioimmunoassay (DSL-
8600 Active Aldosterone kit; Diagnostic Systems Labora-
tory, Webster, TX) with a linear range of 69 to 4450 pmol/L,
intra-assay coefficient of variation 4% to 8%, and interassay
coefficient of variation 7% to 10%.
Cardiovascular Outcomes
The primary outcome in this analysis, as in the parent clinical
trial, was a composite of coronary heart disease death,
nonfatal myocardial infarction, ischemic stroke, hospitaliza-
tion for unstable angina, and resuscitated cardiac arrest.
Prespecified secondary outcomes included all-cause mortal-
ity, unanticipated coronary revascularization, and hospitaliza-
tion for congestive heart failure. The components of the
primary endpoint, all-cause mortality and unanticipated coro-
nary revascularization, were adjudicated by a blinded inde-
pendent Event Adjudication Committee. Hospitalization for
congestive heart failure was based on investigator reports. Of
note, dalcetrapib treatment had no significant effect on any of
these outcome measures.
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Statistical Analysis
The distribution of aldosterone was displayed as a histogram
and examined to determine the need for transformation to
reduce the influence of skew. Demographics, medical history,
and laboratory and treatment variables were evaluated in each
quartile of the aldosterone distribution.
Kaplan-Meier curves were constructed for the primary and
secondary ischemic outcomes across quartiles of aldosterone
in order to graphically evaluate differences in the survival
curves for increasing levels of aldosterone. Cox proportional
hazards regression was used for both unadjusted and
adjusted inference about the association between aldos-
terone (measured continuously) and clinical outcomes.
Hence, hazard ratios for all outcomes, along with P-values
and 95% confidence intervals, were based on the Wald
statistic. A log2 transformation of aldosterone was used to
reduce skew; thus, hazard ratios for each outcome measure
are interpretable as the relative hazard for a doubling of
baseline aldosterone concentration. Adjusted analyses
included covariates for demographics, medical history, labo-
ratory results, and treatment variables, which were chosen on
the basis of a statistically significant relationship with
aldosterone level or on the basis of clear clinical importance
of the variable and its association with cardiovascular
endpoints. Based on these criteria, models were adjusted
for the following 17 variables: age, sex, race, history of
hypertension, diabetes, current smoking, history of cardio-
vascular event (stroke, myocardial infarction, or coronary
revascularization procedure) prior to the index ACS event,
myocardial infarction at the index ACS event, presence or
absence of New York Heart Association Class I or II
symptoms of heart failure at randomization, heart rate, QRS
duration, estimated glomerular filtration rate, and treatment
with an angiotensin-converting enzyme inhibitor or receptor
blocker, b-blocker, diuretic, or dalcetrapib. Results are
reported as 95% confidence intervals and 2-sided P-value
with P<0.05 considered statistically significant.
Results
The distribution of aldosterone levels at baseline is shown in
Figure 1. Median aldosterone was 267 pmol/L; interquartile
range was 201 to 371 pmol/L.
Table 1 shows baseline characteristics of the patients in
aggregate and according to quartile of aldosterone, along
with the association between each characteristic and mean
aldosterone concentration. There was broad use of evi-
dence-based treatments for ACS, including dual antiplatelet
therapy, statins, b-blockers, and angiotensin-converting
enzyme inhibitors or receptor blockers. A large majority of
patients (97.5%) were free of any symptoms of heart failure
with usual activities. NYHA Class II symptoms were present
in 102 patients (2.5%). Higher baseline levels of aldosterone
were associated with female sex, white race, history of
hypertension or diabetes, higher heart rate or QRS duration,
lower estimated glomerular filtration rate, and treatment
with a diuretic. Lower baseline levels of aldosterone were
associated with current smoking, myocardial infarction at
index ACS, and treatment with an angiotensin converting
enzyme inhibitor or receptor blocker.
Patients included in this analysis were followed for a
median of 37 months. During that time there were 366
patients (9.0%) with a primary outcome, 119 patients (2.9%)
who died, 384 patients (9.4%) with unanticipated coronary
revascularization, and 72 patients (1.8%) hospitalized for
congestive heart failure. Table 2 shows the relationships
between aldosterone and primary and secondary outcomes in
unadjusted and adjusted models. Figure 2 depicts the time to
occurrence of ischemic events or death according to quartiles
of aldosterone.
Doubling of aldosterone was not associated with risk of a
primary endpoint, either in univariate analysis (hazard ratio
1.03, 95% confidence interval [CI] 0.88-1.20, P=0.70) or after
adjustment for the 17 demographic, medical history, labora-
tory, and drug treatment variables (hazard ratio 0.92, 95% CI
0.78-1.09, P=0.34). Similarly, there was no significant rela-
tionship between aldosterone and either total mortality or
unanticipated coronary revascularization.
Because the ALBATROSS trial suggested that early
aldosterone antagonism might be beneficial in patients
with ST elevation myocardial infarction without heart
failure,18 we performed a sensitivity analysis on the 1757
patients who presented with ST elevation myocardial infarc-
tion. Similar to the full cohort, a doubling of aldosterone was
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Figure 1. Distribution of plasma aldosterone concentrations.
Measurements were made 4 to 12 weeks after an index ACS
event. Median and interquartile range are indicated in red.
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not associated with the primary composite endpoint in this
subset of patients (hazard ratio 0.91, 95% CI 0.70-1.19,
P=0.48).
In univariate analysis, aldosterone was associated with
increased risk of hospitalization for heart failure (hazard ratio
for doubling of aldosterone concentration 1.62, 95% CI 1.18-
2.22, P=0.003, Table 2). However, after adjustment for the 17
aforementioned demographic, clinical, laboratory, and drug
treatment variables, the association was no longer significant
(hazard ratio 1.38, 95% CI 0.96-1.99, P=0.08).
Table 1. Baseline Characteristics According to Quartile of Aldosterone and Association With Aldosterone Levels
All
n=4073
Aldosterone Quartiles Association With Aldosterone
Quartile 1
n=1029
Quartile 2
n=1020
Quartile 3
n=1021
Quartile 4
n=1003
Estimate (CI)*
n=4073 P Value
Demographics
Age, mean 60.39.1 60.38.9 60.69.3 60.49.1 60.09.1 0.21 (0.42 to 0.84) 0.52
Female, n (%) 812 (19.9) 193 (18.8) 197 (19.3) 196 (19.2) 226 (22.5) 17.57 (2.69-32.46) 0.02
Race, n (%)†
White 3756 (92.2) 938 (91.2) 939 (92.1) 937 (91.2) 942 (93.9) 27.08 (7.51-46.66) 0.007
Black 72 (1.8) 27 (2.6) 18 (1.8) 15 (1.5) 12 (1.2)
Other 245 (6.0) 64 (6.2) 63 (6.2) 69 (6.8) 49 (4.9)
Medical history, n (%)
Hypertension 2827 (69.4) 681 (66.2) 720 (70.6) 701 (68.7) 725 (72.3) 16.2 (4.23-28.1) 0.008
Diabetes mellitus 1025 (25.2) 255 (24.8) 243 (23.8) 249 (24.4) 278 (27.7) 16.0 (1.98-30.1) 0.03
Current smoking 869 (21.3) 869 (21.3) 189 (18.5) 189 (18.5) 194 (19.3) 14.6 (27.5 to 1.65) 0.03
Stroke 119 (2.9) 26 (2.5) 35 (3.4) 27 (2.6) 31 (3.1) 2.81 (29.4 to 35.1) 0.86
Myocardial infarction prior to index ACS 649 (15.9) 156 (15.2) 166 (16.3) 156 (15.3) 171 (17.1) 11.7 (4.47 to 27.8) 0.16
PCI prior to index ACS event 632 (15.5) 149 (14.5) 162 (15.9) 152 (14.9) 169 (16.9) 12.5 (0.19 to 29.3) 0.14
CABG prior to index ACS event 119 (2.9) 57 (5.5) 57 (5.6) 61 (6.0) 72 (7.2) 21.6 (3.39 to 46.6) 0.09
Myocardial infarction at index ACS 3522 (86.5) 897 (87.2) 882 (86.5) 899 (88.1) 844 (84.2) 23.2 (43.3 to 3.03) 0.02
Clinical and laboratory characteristics at randomization
Systolic BP, mm Hg, meanSD 12817.1 12816.4 12816.7 128.517.7 12817.5 0.08 (0.25 to 0.42) 0.63
Diastolic BP, mm Hg, meanSD 76.89.6 76.69.3 76.69.1 77.310.1 76.79.8 0.053 (0.54 to 0.65) 0.86
Body mass index, kg/m2, meanSD 28.85.0 28.65.2 28.94.9 28.54.9 29.15.0 0.59 (0.56 to 1.74) 0.31
HF NYHA I, n (%) 543 (13.3) 131 (12.7) 149 (14.6) 133 (13.0) 130 (13.0) 18.9 (0.89 to 38.7) 0.06
HF NYHA II, n (%) 102 (2.5) 20 (2.0) 27 (2.7) 28 (2.7) 27 (2.7) 43.5 (9.08 to 96.0) 0.10
Heart rate 61.3 (11.0) 60.6 (10.6) 60.4 (10.4) 61.4 (11.7) 62.9 (11.2) 1.35 (0.83-1.87) <0.001
QRS interval 96.0 (16.9) 94.5 (14.8) 96.3 (17.1) 95.7 (16.2) 97.4 (19.2) 0.81 (0.47-1.15) <0.001
eGFR, mL/min per 1.73 m2, meanSD 81.718.5 85.318.4 83.018.2 81.018.1 77.518.5 1.87 (2.18 to 1.57) <0.001
Serum potassium, mmol/L, meanSD 4.40.4 4.40.4 4.40.4 4.40.4 4.40.4 6.96 (7.96 to 21.9) 0.36
Medications at randomization, n (%)
ACEI/ARB 3103 (76.2) 821 (79.8) 773 (75.8) 794 (77.8) 715 (71.3) 18.7 (32.2 to 5.15) 0.007
Diuretics 802 (19.7) 131 (12.7) 175 (17.2) 203 (19.9) 293 (29.2) 94.0 (75.0-112.9) <0.001
b-Blockers 3579 (87.9) 920 (89.4) 898 (88.0) 895 (87.7) 866 (89.3) 16.4 (34.4 to 1.52) 0.07
Randomized to dalcetrapib 2026 (49.7) 526 (51.1) 508 (49.8) 497 (48.7) 495 (49.4) 2.27 (9.19 to 13.7) 0.70
ACEI/ARB indicates angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; ACS, acute coronary syndrome; BP, blood pressure; CABG, coronary artery bypass grafting; HF,
congestive heart failure; CI, confidence interval; eGFR, estimated glomerular filtration rate; NYHA, New York Heart Association; PCI, percutaneous coronary intervention.
*For categorical variables, estimate is the difference in mean aldosterone level (pmol/L) between groups. For continuous variables, the estimate is the linear regression coefficient relating
a 1-unit increase in the variable to the associated change in mean aldosterone level.
†Race was dichotomized and estimate presented as white/nonwhite due to small percentages of nonwhite patients.
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Discussion
Although aldosterone levels predict cardiovascular risk in
patients with chronic heart failure,23 most patients with ACS
do not develop heart failure. The relationship of aldosterone
to prognosis of patients with recent ACS without heart failure
at baseline was previously undefined. Here we determined
that aldosterone levels do not predict major cardiovascular
events in such patients.
The lack of association between aldosterone and recurrent
cardiovascular events in this cohort might reflect the high
prevalence of treatment with antagonists of other neurohor-
mones including b-blockers, angiotensin-converting enzyme
inhibitors, and angiotensin receptor blockers. The present
findings may help to explain the neutral results of the
ALBATROSS trial that evaluated treatment with aldosterone
antagonists beginning immediately after acute myocardial
infarction and continuing for 6 months in patients without
initial heart failure.18
In 3 important ways, the present analysis differs from and
adds to prior studies that examined the relationship of
aldosterone levels to outcomes after ACS.12-14,24-26 First, the
current analysis cohort is much larger and reflects a globally
diverse population with broad application of evidence-based
treatments. Second, in this analysis aldosterone was measured
in the subacute period after ACS, whereas in prior studies
aldosterone had been measured at the time of presentation
with ACS.13,14,24,25 In the immediate period after ACS, left
ventricular function, hemodynamics, manifestations of heart
failure, and aldosterone levels themselves are in flux.12,26
Moreover, many patients with ACS begin treatment with an
angiotensin-converting enzyme inhibitor or an angiotensin
receptor blocker during hospitalization for ACS, and these
drugs suppress aldosterone concentration.12 Thus, information
derived from aldosterone levels when patients are at a
physiologic and therapeutic steady state may be complemen-
tary to measurements of the hormone immediately after ACS.
Third, prior analyses of aldosterone after ACS included patients
Table 2. Unadjusted and Adjusted Hazard Ratios for Primary
and Secondary Outcomes
Outcome Hazard Ratio (CI)* P Value
Primary composite endpoint
Unadjusted 1.03 (0.88-1.20) 0.70
Adjusted 0.92 (0.78-1.09) 0.34
All-cause mortality
Unadjusted 0.92 (0.70-1.22) 0.57
Adjusted 0.79 (0.58-1.06) 0.12
Unanticipated coronary revascularization
Unadjusted 0.93 (0.80-1.09) 0.38
Adjusted 0.88 (0.75-1.04) 0.13
Heart failure hospitalization
Unadjusted 1.62 (1.18-2.22) 0.003
Adjusted 1.38 (0.96-1.99) 0.079
*Hazard ratio for doubling of baseline aldosterone; CI, 95% confidence interval.
Q1 1029 938 891 753 241
Q2 1020 934 896 747 236
Q3 1021 942 914 700 212
Q4 1003 927 883 639 193
Patients at risk
Q1 1029 950 909 765 245
Q2 1020 945 915 760 245
Q3 1021 957 926 718 214
Q4 1003 942 902 654 198
Q1 1029 998 979 829 272
Q2 1020 991 975 826 268
Q3 1021 996 981 761 235
Q4 1003 974 958 709 217
Primary composite endpoint All-cause mortality
Unanticipated coronary
revascularization
Time (months)      Time (months)       Time (months)       
A B C
Figure 2. Cumulative freedom from occurrence of the following types of events, according to quartile of aldosterone at baseline. A, Primary
endpoint (coronary heart disease death, nonfatal myocardial infarction, ischemic stroke, hospitalization for unstable angina, or resuscitated
cardiac arrest). B, All-cause mortality. C, Unanticipated coronary revascularization. P-values (log-rank analysis) indicate the likelihood that at
least 1 quartile differs from the others.
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with advanced heart failure and low ejection fraction13,14 for
whom a relation of aldosterone to risk27 and a benefit of
treatment with an aldosterone antagonist17 have been estab-
lished. In contrast, the present analysis was restricted to
patients without advanced heart failure, who comprise a
majority of those with ACS and in whom a potential benefit of
aldosterone antagonists has not been determined.
Strengths and Limitations
Strengths of this analysis include its large sample size,
substantial primary event rate, and wide distribution of
aldosterone concentrations (~3-fold difference between the
centroids of the first and fourth quartiles).
Among limitations, the timing of aldosterone measurement
and duration of follow-up did not allow us to determine
whether aldosterone is related to in-hospital or early
posthospital outcomes following ACS or to long-term out-
comes beyond the 37-month median follow-up. We did not
measure other neurohormones, including renin and cortisol,
which may have interacted with aldosterone to influence the
occurrence of cardiovascular events.
Hospitalization for heart failure was determined from
investigator reports and was not independently adjudicated.
The study protocol did not require measurement of left
ventricular ejection fraction, and therefore it was not possible
to distinguish heart failure events with preserved ejection
fraction from those with reduced ejection fraction. The
relatively small number of hospitalizations for heart failure
afforded limited power to detect an association with aldos-
terone after adjustment for covariates. The fact that aldos-
terone was significantly associated with the risk of
hospitalization for heart failure in univariate but not adjusted
analysis means that aldosterone does not add to the prediction
of heart failure events after other, commonly measured clinical
variables have been taken into account. However, this finding
does not necessarily imply absence of a biologically important
relationship between aldosterone and heart failure events
because the influence of aldosterone might be underestimated
in multiple regression due to correlation between aldosterone
and covariates. Thus, whether long-term treatment with an
aldosterone antagonist would benefit patients with ACS
without initial heart failure remains an open question, requiring
further randomized clinical trials to provide an answer.
Conclusion
Among patients with ACS but without advanced stages of
heart failure, aldosterone levels measured 4 to 12 weeks after
the index event are unrelated to the risk of subsequent major
cardiovascular events.
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